BioFluidica

BioFluidica is a privately held biotechnology and liquid biopsy company. The Biofluidica platform has been clinically tested on nine different cancer and prenatal patient samples and is currently used for a large variety of research applications to advance the field of liquid biopsy. We are expert consultants in exosome isolation, fetal cell isolation, CTC isolation, and next-generation liquid biopsy. We develop and launch innovative scientific instruments, reagents, and software systems designed to provide exceptional value for scientists, clinicians, and patients. BioFluidica equipped the liquid biopsy core facility at the University of Kansas Medical Center (KUMC) with LiquidScan™ systems to serve their clinical research needs. This extensive experience enables BioFluidica to offer similar Services from their San Diego Core facility. BioFluidica is a privately held biotechnology company that has developed a revolutionary liquid biopsy platform allowing for the isolation and analysis of all liquid biopsy biomarkers, including rare cells, extracellular vesicles (EVs; exosomes), and cfDNA, on one fully automated platform. We are expert consultants in exosome isolation, fetal cell (trophoblast) isolation, CTC isolation, and next-generation liquid biopsy.